Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Biochemical Pharmacology|November 15, 1985
N-Ethyl-17(R,S)-methyl-(6aR,10aR)-delta 8-tetrahydrocannabinol-18-oic amide. Brain pharmacokinetics in mice, triglyceride/phospholipid partitioning and generalization to the discriminative stimulus properties of delta 9-THC in ratsI Franke, A Grothey, S Koch, et al.
Journal of Cancer Research and Clinical Oncology|May 11, 1999
The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumorsA Grothey, W Voigt, C Schöber, et al.
Onkologie|February 1, 1990
Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine-arabinoside in the treatment of patients with myelodysplastic syndromes. A phase II studyK Höffken, F Overkamp, J Stirbu, et al.
European Journal of Cancer Care|September 4, 2009
Impact of quality of life parameters and coping strategies on postchemotherapy nausea and vomitingK Jordan, A Grothey, T Pelz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell linesW Voigt, A Bulankin, T Müller, et al.
The Cochrane Database of Systematic Reviews|April 23, 2005
Chemotherapy for advanced gastric cancerA D Wagner, W Grothe, S Behl, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 6, 2007
A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesisK Jordan, A Hinke, A Grothey, et al.
Oncogene|October 20, 2000
C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell linesA Grothey, R Hashizume, H Ji, et al.
European Journal of Cancer (Oxford, England : 1990)|January 25, 2011
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803D Sargent, Q Shi, G Yothers, et al.
ESMO Open|August 27, 2022
MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancerJ Tabernero, A Grothey, D Arnold, et al.
Pageof 5